Federal Health Care Policy Priorities
ACTION AGENDA

The Public Sector HealthCare Roundtable is a non-profit, non‐partisan coalition of public sector purchasers from across the U.S. including states, counties, and municipalities that collectively spend over $14 billion annually on health care benefits to provide coverage for millions of employees, retirees, and their dependents.

The Roundtable is committed to ensuring that all public sector employees, retirees, and their dependents have access to affordable, quality health care coverage. The members of the Public Sector HealthCare Roundtable have a long-term commitment to maintaining programs that enable public workers, retirees, and their families to obtain high-quality health coverage at a cost that is affordable and sustainable for the workers, their families, and their employers. As such, the Roundtable is committed to the following policy priorities in 2018 to ensure a more sustainable, rational health care system for all Americans:

  • Quality, Affordable Health Care Coverage: We support efforts to ensure that all Americans have access to quality, affordable health care coverage.
  • Action Items: Oppose legislative or regulatory efforts aimed at undermining the ability for all Americans to obtain coverage; support efforts to provide incentives to purchase coverage and sustain federal and state marketplaces; support efforts to stabilize insurance markets and oppose those that undermine them.
  • Relevant Legislation: ‘Bipartisan Health Care Stabilization Act of 2017 (H.R. 4695)
  • Tools: Letters to Congress, meetings with congressional staff, signing stakeholder letters with allies, Public Sector Health Care Roundtable member outreach and education.
  • Health System Innovation and Sustainability: We support policies that constrain health care cost growth and ensure the sustainability of public programs, including the movement to innovative payment models based on value and quality, rather than volume.
  • Action Items: Support efforts to develop innovative models via CMMI; identify and consider support of bipartisan legislative proposals that move to value-based payment models; support CMS efforts to revise and improve value-based payment models, such as the recently announced Bundled Payment Care Improvement model.
  • Relevant Legislation: The Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (S. 870); Patient Choice and Quality Care Act of 2017 (S. 1334)
  • Tools: Letters to CMS, meetings with CMS officials, meetings with congressional staff, signing stakeholder letters with allies, Public Sector Health Care Roundtable member outreach and education, white papers with key allies.
  • Pharmaceutical Cost Containment: We support congressional and regulatory efforts to establish and sustain greater competition in the pharmaceutical – and especially the biopharmaceutical – marketplace. We also support ongoing efforts that seek to increase the pace of approval with the pace of discovery of safe, innovative, and cost-effective pharmaceutical and device products in the U.S.
  • Action Items: Enthusiastically support legislation to shorten market exclusivity for biologic drugs (Improving Access to Affordable Prescription Drugs Act), allow Medicare to negotiate with manufacturers, targeting abusive delay tactics that are being used to block entry of affordable generic drugs; support efforts to increase transparency by collaborating with key allies, such as HCCI.
  • Relevant Legislation: The Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act) (S. 974); the Price Relief, Innovation, and Competition for Essential Drugs Act (S. 3094 and H.R. 5573); the Improving Access to Affordable Prescription Drugs Act (S. 771)
  • Tools: Meetings with FDA officials, letters to Congress, meetings with congressional staff, signing stakeholder letters with allies, Public Sector Health Care Roundtable member outreach and education, white papers with key allies.
  • Health Care Quality and Improved Outcomes: We support the further development and use of quality measures, and particularly those in high-impact areas such as the complex chronically ill, as well as policies that establish and disseminate comparative effectiveness research in order to identify the most appropriate treatments at the lowest cost that will achieve the highest-quality outcomes for patients.
  • Action Items: Support efforts to fund public-private entities such as the National Quality Forum; Support the continued funding of the Patient Centered Outcomes Research Institute (PCORI) and efforts to compare cost data;
  • Relevant Legislation: Supporting efforts of the Agency for Healthcare Research and Quality in implementation the National Quality Strategy
  • Tools: Letters to Congress, meetings with congressional staff, signing stakeholder letters with allies, Public Sector Health Care Roundtable member outreach and education, white papers with key allies.
  • Health Care Tax Policy: We strongly oppose approaches such as the so-called “Cadillac tax” and “health insurance tax” on health insurance premiums which would impose enormous financial burdens on public workers, retirees, and their families while also creating significant, longer-term disincentives for public sector purchasers to develop and implement innovative benefit designs that encourage the utilization of high-value health care services.
  • Action Items: Support efforts to repeal and/or delay the “Cadillac Tax”; support efforts to repeal the health insurance premium tax.
  • Relevant Legislation: The Jobs and Premium Protection Act (H.R. 246); The Healthcare Tax Relief Act (S. 1859); Middle Class Health Benefits Tax Repeal Act of 2017, (H.R.173, S. 58)
  • Tools: Letters to Congress, meetings with congressional staff, signing stakeholder letters with allies, Public Sector Health Care Roundtable member outreach and education, white papers with key allies, white papers with key allies.